Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Now Rated “Buy” by Wall Street Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have earned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company.

Several analysts recently issued reports on the company. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS BAYRY opened at $12.64 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm’s 50-day moving average price is $14.01 and its two-hundred day moving average price is $12.51. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23. The stock has a market capitalization of $49.68 billion, a P/E ratio of -24.78, a P/E/G ratio of 1.90 and a beta of 0.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, August 4th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin.